ATE455765T1 - Aryloxy- und arylthioxyacetophenon-verbindungen zur behandlung von krebs - Google Patents

Aryloxy- und arylthioxyacetophenon-verbindungen zur behandlung von krebs

Info

Publication number
ATE455765T1
ATE455765T1 AT07118973T AT07118973T ATE455765T1 AT E455765 T1 ATE455765 T1 AT E455765T1 AT 07118973 T AT07118973 T AT 07118973T AT 07118973 T AT07118973 T AT 07118973T AT E455765 T1 ATE455765 T1 AT E455765T1
Authority
AT
Austria
Prior art keywords
compounds
formula
arylthioxyacetophenone
aryloxy
treating cancer
Prior art date
Application number
AT07118973T
Other languages
English (en)
Inventor
Martin Eberle
Felix Bachmann
Alessandro Strebel
Subho Roy
Goutam Saha
Subir Kumar Sadhukhan
Rohit Saxena
Sudhir Srivastava
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Application granted granted Critical
Publication of ATE455765T1 publication Critical patent/ATE455765T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT07118973T 2003-12-22 2004-12-21 Aryloxy- und arylthioxyacetophenon-verbindungen zur behandlung von krebs ATE455765T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03405911 2003-12-22
EP03405912 2003-12-22
EP04405517 2004-08-19

Publications (1)

Publication Number Publication Date
ATE455765T1 true ATE455765T1 (de) 2010-02-15

Family

ID=34714028

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07118973T ATE455765T1 (de) 2003-12-22 2004-12-21 Aryloxy- und arylthioxyacetophenon-verbindungen zur behandlung von krebs
AT04804957T ATE381554T1 (de) 2003-12-22 2004-12-21 Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04804957T ATE381554T1 (de) 2003-12-22 2004-12-21 Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen

Country Status (9)

Country Link
US (1) US8486996B2 (de)
EP (2) EP1697336B1 (de)
JP (1) JP4805166B2 (de)
CN (1) CN101061101B (de)
AT (2) ATE455765T1 (de)
CA (1) CA2545821C (de)
DE (2) DE602004025302D1 (de)
ES (2) ES2298853T3 (de)
WO (1) WO2005061476A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2388263A1 (de) 2005-08-04 2011-11-23 Sirtris Pharmaceuticals, Inc. Imidazo[2,1-b]thiazol-Derivate als Sirtuin-Modulatoren
RU2008139599A (ru) 2006-03-07 2010-04-20 Эррэй Биофарма Инк. (Us) Гетеробициклические производные пиразола и способы их применения
RU2448111C2 (ru) * 2006-08-21 2012-04-20 Дженентек, Инк. Соединения азабензофуранила и способ их применения
MX2009001875A (es) 2006-08-21 2009-03-02 Genentech Inc Compuestos de aza-benzotiofenilo y metodos de uso de los mismos.
CN101605794B (zh) * 2006-08-21 2013-06-12 健泰科生物技术公司 氮杂苯并呋喃基化合物及使用方法
US20080085886A1 (en) * 2006-08-21 2008-04-10 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
NZ578744A (en) * 2007-01-31 2012-02-24 Vertex Pharma 2-aminopyridine derivatives useful as kinase inhibitors
WO2009073300A1 (en) * 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
MX2010014565A (es) 2008-07-01 2011-03-04 Genentech Inc Isoindolona y metodos de uso.
BRPI0910175A2 (pt) 2008-07-01 2017-03-21 Genentech Inc composto de fórmula i e ii, composição farmacêutica, método de inibição do crescimento de células anormais ou de tratamento de um distúrbio hiperproliferativo em um mamífero e método de tratamento de uma doença inflamatória em um mamífero
EP2328896B1 (de) 2008-07-23 2013-10-23 Vertex Pharmaceuticals Incorporated Tricyclische pyrazolopyridine als kinaseinhibitoren
NZ590784A (en) 2008-07-23 2012-12-21 Vertex Pharma Pyrazolopyridine kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010017350A1 (en) * 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
EP2427464A1 (de) 2009-05-06 2012-03-14 Vertex Pharmaceuticals Incorporated Pyrazolopyridine
JP2013518114A (ja) 2010-01-27 2013-05-20 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾロピリミジンキナーゼ阻害剤
AU2011209649A1 (en) 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
JP5769733B2 (ja) 2010-01-27 2015-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ピラゾロピリジンキナーゼ阻害剤
BR112021005274A2 (pt) 2018-09-22 2021-06-15 Torrent Pharmaceuticals Limited métodos para produção de compostos de pirazol

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2350109A (en) * 1999-05-17 2000-11-22 Bayer Ag Pharmaceutically active benzofuranyl sulfonates
AU6315300A (en) 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
GB9920872D0 (en) * 1999-09-04 1999-11-10 Glaxo Group Ltd Benzophenones as inhibitors of reverse transcriptase
DE19947154A1 (de) * 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
JP4535680B2 (ja) * 2001-04-16 2010-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規１ｈ−インダゾール化合物
KR20040094720A (ko) * 2002-02-22 2004-11-10 바이엘 파마슈티칼스 코포레이션 과다증식성 질환 치료에 유용한 접합 3환계 헤테로사이클
US7144885B2 (en) * 2002-02-22 2006-12-05 Bayer Pharmaceuticals Corporation Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
ES2291690T3 (es) * 2002-07-11 2008-03-01 Bayer Pharmaceuticals Corporation Derivados de furopiridina para el tratamiento de trastornos hiperproliferativos.

Also Published As

Publication number Publication date
WO2005061476A2 (en) 2005-07-07
JP4805166B2 (ja) 2011-11-02
EP1697336A2 (de) 2006-09-06
US8486996B2 (en) 2013-07-16
JP2007517787A (ja) 2007-07-05
CA2545821A1 (en) 2005-07-07
CA2545821C (en) 2010-09-21
EP1697336B1 (de) 2007-12-19
DE602004010845D1 (de) 2008-01-31
CN101061101B (zh) 2011-09-07
WO2005061476A3 (en) 2006-01-26
DE602004025302D1 (de) 2010-03-11
CN101061101A (zh) 2007-10-24
DE602004010845T2 (de) 2008-12-04
ATE381554T1 (de) 2008-01-15
US20060205739A1 (en) 2006-09-14
ES2298853T3 (es) 2008-05-16
EP1894917A1 (de) 2008-03-05
ES2338060T3 (es) 2010-05-03
EP1894917B1 (de) 2010-01-20

Similar Documents

Publication Publication Date Title
ATE455765T1 (de) Aryloxy- und arylthioxyacetophenon-verbindungen zur behandlung von krebs
MXPA04000677A (es) Tienopirimidindionas y su uso en modulacion de enfermedades autoinmunes.
AP1635A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease.
MXPA02012425A (es) Compuestos nuevos.
DE602004001857D1 (de) Thienopyrimidindione und deren verwendung bei der modulierung von autoimmunerkrankungen
SE0202133D0 (sv) Novel compounds
ATE469892T1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
CY1109906T1 (el) Παραγωγα c3-kyano εποθιλονης
NO20054361D0 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
MY141233A (en) Enantiomers of selected fused heterocyclics and uses thereof
DE60014393D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
DE602005022284D1 (de) Substituierte benzimidazole und deren verwendung zur induktion von apoptose
CY1109300T1 (el) Νεοι συντηγμενοι ετεροκυκλικοι δακτυλιοι και χρησεις αυτων
PL376324A1 (en) Piperazinyl and diazapanyl benzamides and benzthioamides
DK1636215T3 (da) Furazanobenzimidazoler
DE602004029355D1 (de) Sulfopyrrolderivate
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
SE0101038D0 (sv) Novel compounds
SE0300456D0 (sv) Novel compounds
MXPA05010020A (es) Derivados de oxamida.
EA200600992A1 (ru) Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
SE0303280D0 (sv) Novel compounds
MXPA02012426A (es) Compuestos nuevos.
SE0303090D0 (sv) Novel compounds
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1894917

Country of ref document: EP